X Fan1, X Song2, M Zhao3, L F Jarskog4, R Natarajan1, N Shukair1, O Freudenreich5, D C Henderson6, D C Goff7. 1. Psychotic Disorders Program, University of Massachusetts Medical School/UMass Memorial Medical Center, Worcester, MA, USA. 2. Department of Psychiatry, The1st Affiliated Hospital of Zhengzhou University, Zhengzhou, China. 3. Shanghai Mental Health Center, Shanghai, China. 4. Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, USA. 5. Schizophrenia Program, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA. 6. Department of Psychiatry, Boston University/Boston Medical Center, Boston, MA, USA. 7. Department of Psychiatry, New York University Medical School and Nathan Kline Institute, New York, NY, USA.
Abstract
OBJECTIVE: This study examined the effect of adjunctive telmisartan on psychopathology and cognition in olanzapine- or clozapine-treated patients with schizophrenia. METHOD: In a 12-week randomized, double-blind, placebo-controlled study, patients diagnosed with schizophrenia or schizoaffective disorder received eithertelmisartan (80 mg once per day) or placebo. Psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS) and the Scale for Assessment of Negative Symptoms (SANS), and a neuropsychological battery was used to assess cognitive performance. Assessments for psychopathology and cognition were conducted at baseline and week 12. RESULTS:Fifty-four subjects were randomized, and 43 completed the study (22 in thetelmisartan group, 21 in the placebo group). After 12-weeks of treatment, the telmisartan group had a significant decrease in PANSS total score compared withthe placebo group (mean ± SD: - 4.1 ± 8.1 vs. 0.4 ± 7.5, P = 0.038, SCohen's d = 0.57). There were no significant differences between the two groups in change from baseline to week 12 in PANSS subscale scores, SANS total score, or any cognitive measures (P > 0.100). CONCLUSION: The present study suggests that adjunctive treatment with telmisartan may improve schizophrenia symptoms. Future trials with larger sample sizes and longer treatment durations are warranted.
RCT Entities:
OBJECTIVE: This study examined the effect of adjunctive telmisartan on psychopathology and cognition in olanzapine- or clozapine-treated patients with schizophrenia. METHOD: In a 12-week randomized, double-blind, placebo-controlled study, patients diagnosed with schizophrenia or schizoaffective disorder received either telmisartan (80 mg once per day) or placebo. Psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS) and the Scale for Assessment of Negative Symptoms (SANS), and a neuropsychological battery was used to assess cognitive performance. Assessments for psychopathology and cognition were conducted at baseline and week 12. RESULTS: Fifty-four subjects were randomized, and 43 completed the study (22 in the telmisartan group, 21 in the placebo group). After 12-weeks of treatment, the telmisartan group had a significant decrease in PANSS total score compared withthe placebo group (mean ± SD: - 4.1 ± 8.1 vs. 0.4 ± 7.5, P = 0.038, SCohen's d = 0.57). There were no significant differences between the two groups in change from baseline to week 12 in PANSS subscale scores, SANS total score, or any cognitive measures (P > 0.100). CONCLUSION: The present study suggests that adjunctive treatment with telmisartan may improve schizophrenia symptoms. Future trials with larger sample sizes and longer treatment durations are warranted.
Authors: Waleed A I Khallaf; Basim A S Messiha; Amira M H Abo-Youssef; Nesrine S El-Sayed Journal: Can J Physiol Pharmacol Date: 2017-04-07 Impact factor: 2.273
Authors: Iris E Sommer; Roos van Westrhenen; Marieke J H Begemann; Lot D de Witte; Stefan Leucht; René S Kahn Journal: Schizophr Bull Date: 2013-10-08 Impact factor: 9.306